Oman Diabetes Devices Market Size, Share & Forecast, By Product Type, Care Setting & Technology, 2026-2031

The Oman Diabetes Devices Market is worth USD 68 million in 2025. The estimate covers self-monitoring blood glucose devices, continuous glucose monitoring systems, insulin-delivery devices and connected diabetes-management devices sold for use in hospitals, clinics, pharmacies and homecare. Demand is supported by a 13.4% adult prevalence of raised fasting glucose or diabetes medication use, while recurring strips, sensors, needles and infusion supplies create a durable replacement cycle. Public procurement remains important, but homecare and pharmacy channels increasingly shape product choice and replenishment.

The market is projected to reach USD 80 million by 2031, expanding at a 2.75% CAGR from 2025. Growth is moderate at the total-market level because conventional meters, test strips, syringes and insulin pens are mature and exposed to procurement pressure. The faster-moving revenue pool is continuous glucose monitoring, connected meters, smart pens and automated insulin delivery. These categories are expected to gain mix as clinicians pursue better control, remote review and reduced treatment friction for insulin-intensive patients.

Profit pools will shift toward continuous glucose monitoring sensors, software-enabled monitoring and integrated insulin-delivery ecosystems. Conventional meters create installed-base access, but test strips face tender and retail price competition. CGM sensors generate frequent replacement revenue, while connected platforms can attach onboarding, adherence support and clinician-review services. Homecare revenue is expected to rise as a share of the market, making pharmacy fulfillment, direct-to-consumer replenishment and subscription models strategically more valuable than standalone institutional hardware sales.

The largest constraint is the affordability and reimbursement gap for advanced devices. Oman has a sizeable disease burden, but only 53.2% of people with raised glucose were currently treated in the 2025 STEPS survey, and only 26.0% achieved fasting glucose below 7.0 mmol/L. Premium systems require recurring sensor, infusion-set or pump consumable expenditure, which can exceed the budget available through conventional public procurement. Imported supply and distributor dependence further increase landed cost and continuity risk.

Oman ranks fourth among the selected peer markets of Saudi Arabia, the UAE, Kuwait, Oman and Qatar by 2025 revenue. Its USD 68 million market is smaller than Saudi Arabia, the UAE and Kuwait, but larger than Qatar in the modeled comparison. Oman’s 2.75% forecast CAGR trails the faster GCC average, reflecting smaller population scale and a more mature conventional-device base. The opportunity is therefore selective: suppliers should focus on high-risk cohorts, specialist clinics and cost-effective connected monitoring rather than assume broad premium adoption.

The strongest structural driver is the combination of diabetes incidence, underdiagnosis and obesity-linked risk. More than 6,500 new diabetes cases are recorded annually, while 64.7% of adults were overweight in the 2025 STEPS survey. Only 55.6% of people with raised glucose had been previously diagnosed, leaving a substantial pool that can enter monitoring pathways through screening and primary care. This supports sustained demand for starter meters, strips, connected monitoring and eventually higher-intensity devices as treatment escalates.